ASk Questions in GYnecologic Oncology (ASQ-GYO)

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorIra Winer

About this trial

The goal of this clinical trial is to determine the effectiveness of the ASk Questions in GYnecologic Oncology question prompt list (ASQ-GYO QPL) at improving patient self-efficacy, distress, physician trust, and knowledge compared to usual care during new patient gynecologic oncology visits. Also to determine the acceptability of the ASQ-GYO QPL with new gynecologic oncology patients.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

18 years of age

Understands spoken and written English

Able to consent to study participation

Biopsy confirmed gynecologic cancer diagnosis (ovarian, endometrial, cervical, vulvar, or vaginal cancer or Gestational Trophoblastic Disease) OR have imaging and/or laboratory findings highly concerning for a cancer diagnosis and have not seen a Gynecologic Oncologist

Disqualifiers

pathologic diagnosis of dysplasia only (cervical, vulvar, or endometrial)

History and/or imaging/laboratory findings more indicative of a non-cancer diagnosis

Previous treatment discussion with a Gynecologic Oncologist

Trial design

Design model

Parallel

Treatments tested in this trial

  • Administration of the ASk Questions in GYnecologic Oncology (ASQ-GYO) Question Prompt List

    Behavioral

    Participants are randomized and will receive the ASQ-GYO prompt list within 2 weeks prior to their new patient appointment with the gynecology oncology physician.

Treatment groups

70 Participants
are divided into 2 treatment groups
Group A: Administration of the ASk Questions in GYnecologic Oncology (ASQ-GYO) Question Prompt ListExperimental treatment 1 intervention
Group B: No administration of the ASk Questions in GYnecologic Oncology (ASQ-GYO) Question Prompt ListNo intervention 0 interventions

Trial outcomes

Primary outcomes

1

Change in pre- and post-visit self-efficacy scores and compared by trial group

The Perceived Efficacy in Patient-Provider Interactions (PEPPI) instrument is a validated, 20-item, 5-point Likert scale tool designed to measure patient's self-efficacy in obtaining medical information and attention to their medical concerns from physicians.

Time frame
All participants will complete the PEPPI instrument twice: within 2 weeks of their first visit and again within 1 week after the visit.

Secondary outcomes

1

Change in pre- and post-visit National Comprehensive Cancer Network (NCCN) Distress Thermometer scores compared by trial group

The NCCN Distress Thermometer is a one-question, 11-point Likert scale for patient-reported distress in the past week including today

Time frame
All participants, Twice: within 2 weeks of the first visit and again within 1 week after the visit
2

Change in pre- and post-visit Trust in a Physician scores compared by trial group

The Trust in a Physician score is a validated, 5-point Likert scale with higher scores indicating more trust. The metric addresses generic physician trust prior to the visit, and trust in the specific physician the patient saw during their visit for after the visit

Time frame
All participants, Twice: within 2 weeks of the first visit and again within 1 week after the visit
3

Knowledge Screen

The Knowledge Screen is a 10-item, 5-point Likert scale, investigator-developed set of questions designed to elicit understanding of the contents of the Question Prompt List with higher scores indicating more understanding.

Time frame
All participants will complete a post-visit knowledge screen once within 1 week after their visit
4

Patient perceptions of the Question Prompt List

This is a 15-item investigator-developed set of questions with 7 items utilizing a 5-point Likert scale and 8 items utilizing binary yes/no questions designed to elicit the acceptability of the Question Prompt List among the patients in the intervention group.

Time frame
The patients in the intervention group will complete this within 1 week after their visit.

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Ira Winer

Lead sponsor

Barbara Ann Karmanos Cancer Institute

Sponsor institution